Alkermes narcolepsy drug data published in The Lancet Neurology

August 24, 2026 6:30 PM

Alkermes plc (Nasdaq: ALKS) announced the publication of phase 2 clinical trial data for its investigational drug alixorexton in The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found